Anecdotally, CTLA-4 inhibition with ipilimumab has demonstrated anti-tumor activity in a small series of MCC cases [18], and is currently being investigated in combination with nivolumab in patients with advanced MCC or virus-associated cancer (ClinicalTrials.gov Identifier: NCT02488759). The gene discussed is CTLA4; the disease is neoplasm.